ArticlePharmaceutical research2010
A novel Doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy.
Article in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 103 citations in OpenAlex.
- A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin.Bioconjugate chemistry · 2026Article
- Bioorthogonal Photoactivation of 2-Nitrobenzyl Caged Doxorubicin Anticancer Prodrugs on Gold Nanostars.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Review
- Breast Cancer Inhibition by Biosynthesized Titanium Dioxide Nanoparticles Is Comparable to Free Doxorubicin but Appeared Safer in BALB/c Mice.Materials (Basel, Switzerland) · 2021Article
- Stimuli-Responsive Biomaterials: Scaffolds for Stem Cell Control.Advanced healthcare materials · 2021Review
- Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib.Molecules (Basel, Switzerland) · 2020Article
- Therapeutic Potential of Zinc Oxide-Loaded Syringic Acid Against in vitro and in vivo Model of Lung Cancer.International journal of nanomedicine · 2020Article
- Size Matters in the Cytotoxicity of Polydopamine Nanoparticles in Different Types of Tumors.Cancers · 2019Article
- Photo-controlled delivery of a potent analogue of doxorubicin.Chemical communications (Cambridge, England) · 2019Article
- Increased fucoxanthin inBiotechnology reports (Amsterdam, Netherlands) · 2019Article
- Article
- Drug Delivery Nanoparticles with Locally Tunable Toxicity Made Entirely from a Light-Activatable Prodrug of Doxorubicin.Pharmaceutical research · 2017Article
- Spatiotemporal Control of Doxorubicin Delivery from "Stealth-Like" Prodrug Micelles.International journal of molecular sciences · 2017Article
- Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.Journal of mass spectrometry : JMS · 2013Article
- Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment.Drug design, development and therapy · 2013Review
- The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics.International journal of nanomedicine · 2013Article
- Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.Future cardiology · 2012Review
- Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles.International journal of nanomedicine · 2012Article
- Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles.International journal of nanomedicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeDoxorubicin (DOX) is a very effective anticancer agent. However, in its pure form, its application is limited by significant cardiotoxic side effects. The purpose of this study was to develop a controllably activatable chemotherapy prodrug of DOX created by blocking its free amine group with a biotinylated photocleavable blocking group (PCB).
methodsAn n-hydroxy succunamide protecting group on the PCB allowed selective binding at the DOX active amine group. The PCB included an ortho-nitrophenyl group for photo cleavability and a water-soluble glycol spacer arm ending in a biotin group for enhanced membrane interaction.
resultsThis novel DOX-PCB prodrug had a 200-fold decrease in cytotoxicity compared to free DOX and could release active DOX upon exposure to UV light at 350 nm. Unlike DOX, DOX-PCB stayed in the cell cytoplasm, did not enter the nucleus, and did not stain the exposed DNA during mitosis. Human liver microsome incubation with DOX-PCB indicated stability against liver metabolic breakdown.
conclusionsThe development of the DOX-PCB prodrug demonstrates the possibility of using light as a method of prodrug activation in deep internal tissues without relying on inherent physical or biochemical differences between the tumor and healthy tissue for use as the trigger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.